Treating Hallucinations and Delusions Associated With Parkinson ’s Disease Psychosis

AbstractPurpose of ReviewWe discuss features of Parkinson ’s disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agent s is examined.Recent FindingsPimavanserin, a 5-HT2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment. Research into novel targets is ongoing.SummaryPDP is a morbid complication of Parkinson ’s disease with complex incompletely understood mechanisms. Treatment is directed towards mitigation of psychosis without worsening of motor features.
Source: Current Psychiatry Reports - Category: Psychiatry Source Type: research